Abbott Laboratories [NYSE: ABT] plunged by -$0.55 during the normal trading session on Monday and reaching a high of $99.50 during the day while it closed the day at $98.94. The company report on October 28, 2022 that Abbott’s FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation.
Abbott’s FreeStyle Libre honored as the “best of the best” since 1970 during the Prix Galien Golden Jubilee Awards.
Revolutionary FreeStyle Libre technology has transformed the lives of approximately 4.5 million people1 living with diabetes globally.
Abbott Laboratories stock has also gained 0.66% of its value over the past 7 days. However, ABT stock has declined by -8.93% in the 3 months of the year. Over the past six months meanwhile, it has lost -12.31% and lost -29.70% year-on date.
The market cap for ABT stock reached $168.81 billion, with 1.75 billion shares outstanding and 1.74 billion shares in the current float. Compared to the average trading volume of 5.54M shares, ABT reached a trading volume of 5885319 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $117.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 26, 2022. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on October 18, 2022, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $110, while Jefferies analysts kept a Hold rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.71, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 3.75. The Price to Book ratio for the last quarter was 4.75, with the Price to Cash per share for the same quarter was set at 5.44. Price to Free Cash Flow for ABT in the course of the last twelve months was 34.32 with Quick ratio for the last quarter at 1.50.
ABT stock trade performance evaluation
Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.66. With this latest performance, ABT shares gained by 2.25% in over the last four-week period, additionally sinking by -12.31% over the last 6 months – not to mention a drop of -23.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 47.04, with the RSI for the last a single of trading hit 48.52, and the three-weeks RSI is set at 46.23 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 101.96, while it was recorded at 98.35 for the last single week of trading, and 112.19 for the last 200 days.
Abbott Laboratories [ABT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +21.36 and a Gross Margin at +53.89. Abbott Laboratories’s Net Margin is presently recorded at +16.35.
Return on Equity for this stock inclined to 20.53, with Return on Assets sitting at 9.53.
Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 2.00.
Earnings per share (EPS) analysis for Abbott Laboratories [ABT] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 8.30%.
Abbott Laboratories [ABT]: Insider Ownership positions
There are presently around $128,408 million, or 75.80% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 152,551,738, which is approximately 0.835% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 135,406,658 shares of the stock with an approximate value of $13.4 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $7.92 billion in ABT stock with ownership of nearly -0.719% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,175 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 47,814,520 shares. Additionally, 1,216 investors decreased positions by around 33,663,084 shares, while 408 investors held positions by with 1,216,361,702 shares. The mentioned changes placed institutional holdings at 1,297,839,306 shares, according to the latest SEC report filing. ABT stock had 97 new institutional investments in for a total of 3,428,180 shares, while 147 institutional investors sold positions of 3,142,542 shares during the same period.